Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119292 | 0.89 | PARK7 (0.46) | PARK7ALDH1A1ALDH2ALDH3A1CA1 | |
| SCHEMBL5125074 | 0.89 | PARK7 (0.73) | PARK7ALDH1A1ALDH2ALDH3A1CA1 | |
| SCHEMBL5111486 | 0.88 | PARK7 (0.44) | PARK7ALDH1A1ALDH2ALDH3A1CA1 | |
| SCHEMBL5118596 | 0.83 | LMNA (0.51) | PARK7ALDH1A1ALDH2ALDH3A1CA1 | |
| SCHEMBL5114499 | 0.82 | PARK7 (0.40) | PARK7ALDH1A1ALDH2ALDH3A1CA1 | |
| SCHEMBL5110054 | 0.82 | PARK7 (0.40) | PARK7ALDH1A1ALDH2ALDH3A1CA1 | |
| SCHEMBL5118438 | 0.81 | PARK7 (0.60) | PARK7ALDH1A1ALDH2ALDH3A1CA1 | |
| SCHEMBL5110046 | 0.80 | PARK7 (0.39) | PARK7ALDH1A1ALDH2ALDH3A1CA1 | |
| SCHEMBL5123616 | 0.80 | PARK7 (0.44) | PARK7ALDH1A1ALDH2ALDH3A1KDM4E | |
| SCHEMBL5114130 | 0.80 | TP53 (0.45) | PARK7ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| EP-1828124-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063863-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | PARK7 2430/4885ALDH1A1 420/4885ALDH2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.